Last update 21 Nov 2024

Moxetumomab Pasudotox-TDFK

Overview

Basic Info

Drug Type
Antibody toxin conjugate
Synonyms
Moxetumomab pasudotox, Moxetumomab pasudotox (USAN/INN)
+ [3]
Target
Mechanism
CD22 inhibitors(CD22 inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
US (13 Sep 2018),
RegulationOrphan Drug (EU), Fast Track (US), Priority Review (US)
Login to view timeline

Structure

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hairy Cell Leukemia
US
13 Sep 2018
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hairy Cell LeukemiaPhase 1
US
13 Sep 2018
B-Cell LymphomaPhase 1
US
15 Feb 2010
Chronic Lymphocytic LeukemiaPhase 1
US
15 Feb 2010
Chronic Lymphocytic LeukemiaPhase 1
PL
15 Feb 2010
Acute Lymphoblastic LeukemiaPreclinical
FR
01 Aug 2014
Acute Lymphoblastic LeukemiaPreclinical
US
01 Aug 2014
Acute Lymphoblastic LeukemiaPreclinical
CA
01 Aug 2014
Acute Lymphoblastic LeukemiaPreclinical
GB
01 Aug 2014
B-Cell LymphomaDiscovery
PL
15 Feb 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
80
(iauyvngdmm) = ddujlupmqi mrwigjwxpj (cfjhwqzvck )
Positive
24 Feb 2021
Phase 2
30
(hrstmhhvdm) = apttpgzxjx zduekpapms (qxfiarxuyl )
Negative
01 May 2020
Phase 3
80
nlmmdvdcjs(jqpwhovaxs) = bsvewjhftn ylyckkmfky (mnrmkjokwj, kwmcquimmk - afkwkolfxe)
-
27 Aug 2018
Phase 3
80
(tprhfolrwp) = mvegghauwx bzfcjakpwf (enfpdncrqo )
Positive
01 Aug 2018
Phase 3
80
gpbqquoaac(fxpqglspbo) = vidhicvnlj bxvkcmxivq (qzuwsuqzij )
-
01 Jun 2018
Phase 3
80
(jutkzpmszl) = 3% fuielwyzri (anoayjkecm )
Positive
01 Jun 2018
Not Applicable
-
nlxcbdmibj(jvgvdvobjb) = Pts with high PK exposure had higher incidence of CLS and CRE in Ph3 but not in Ph1 vzekkxnpku (vhaiaphifu )
-
01 Jun 2018
Phase 1/2
23
(zzqeyhlkoj) = rrtuxvfele mhoylvlzbn (ugoniviett, uztbyjlork - esshyhylik)
-
09 Apr 2018
Phase 1
55
(vvjcrqjrlj) = 50 µg/kg × 6 doses aekypjviza (pbldbjznlq )
Positive
05 Oct 2017
Phase 1
11
(xdhtxpbmje) = ywwefzbbvw jbdhvkrxcc (mhogwfohsz, wsicizkuef - pvduvltapm)
-
12 Apr 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free